Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune...
Morningstar· 1 day agonaNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory ...
Activation-inducible CAR expression enables precise control over engineered CAR T cell function -...
Nature· 3 days agoT cells are modified to express the CAR gene dependent on activation status under the control of an engineered feedback loop and are shown to function in vitro and in vivo to kill tumour cells.
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results...
WKYT Lexington· 2 days agoIn the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents...
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term...
Morningstar· 3 days agoG1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib ...
Roswell Park Study is First to Show That Exercise Strengthens Immune System in Multiple Myeloma...
Newswise· 3 days agoCHICAGO, Ill. — Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type ...
An IL-17-EGFR-TRAF4 axis contributes to the alleviation of lung inflammation in severe influenza -...
Nature· 5 days agoAdaptive transfer experiments using an influenza hemagglutinin antigen-specific mouse model suggest that viral neuraminidase-activated TGF-β from Th1 cells guides Th17 evolution to promote protection from lung inflammation in severe influenza.
Hopewell Therapeutics Announces $25 Million Seed Financing to Advance Next Generation Lipid...
Benzinga· 13 hours agoCompany has built leading edge tissue-targeted Lipid Nanoparticle (ttLNP) technology to enable a new generation of highly targeted genomic medicines Participating venture investors include Mass Ave Capital, 5Y Capital,
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory...
Benzinga· 2 days agoNexImmune, Inc. NEXI, a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific < ...
Memory killer cells can improve survival for melanoma patients
Medical Xpress· 5 days agoCertain immune T cells called tissue-resident memory cells are formed locally in the skin and other...
Why Are Evaxion Biotech Shares Trading Higher Today
Benzinga via Yahoo Finance· 2 days agoEvaxion Biotech A/S (NASDAQ: EVAX) presented clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual...
Yahoo Web Search
Trending Now
